Glucosamine Linked to 25% Faster Dementia Progression — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Florida researchers analyzing deidentified UF Health records from 2012 to 2024 found glucosamine use was associated with a 25% higher likelihood that mild cognitive impairment progressed to dementia.
- Glucosamine use was also tied to a 25% higher mortality risk among patients already diagnosed with Alzheimer's disease and related dementias, though the same mortality link did not appear in the MCI-only group.
- In both patient groups studied, 8% of patients reported using glucosamine — 1,896 people with ADRD and 2,750 people with MCI — prompting the team to use AI to mine records originally collected under co-authors Yi Guo, Ph.D., and Jiang Bian, Ph.D.
- Ramon Sun, Ph.D., senior author and director of UF's Center for Advanced Spatial Biomolecule Research, led the study published in Nature Metabolism, which proposes that excessive 'sugar tagging' of proteins (hyperglycosylation) actively drives Alzheimer's progression.
- Genetically modified mice given glucosamine showed worsened social memory deficits alongside increased protein sugar attachment, while a chemical treatment that suppressed the sugar-tagging process restored memory performance.
- Human Alzheimer's brain tissue from UF's Neuromedicine Brain and Tissue Bank showed significantly more sugar attachment than tissue from healthy controls, reinforcing the metabolic mechanism beyond animal models.
- The researchers emphasized the data shows association, not causation, and called for a controlled human clinical trial to determine whether glucosamine directly accelerates cognitive decline.
Why it matters: With roughly 7 million Americans living with Alzheimer's and millions more taking glucosamine daily for joint pain, the association — replicated in both health records and lab models — raises an immediate clinical question for older adults already showing cognitive symptoms. The 25% jump in progression risk is large enough that researchers say it deserves a formal trial, though they caution no one should stop taking the supplement on this evidence alone.
Ask SkimNews
